

RESEARCH ARTICLE

The Possible Hepatoprotective Effects of Combination of an Oral Krill Oil and Silymarin against Carbon Tetrachloride (CCl₄)-induced Liver Fibrosis/Injury in White Albino Rats: Histopathological, and Biochemical Studies

Kassim H. Ali,^{1*} Faruk H. Al-Jawad,² Haitham M. Kadhim,³ Mohammad A. H. Al-Dabagh⁴

¹*Department of Pharmacology & Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq*

²*Department of Pharmacology & Therapeutics, College of Medicine, Al-Nahrain University, Baghdad, Iraq*

³*Department of Pharmacology & Toxicology, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq*

⁴*Medical Research Unit, College of Medicine, Al-Nahrain University, Baghdad, Iraq*

Received: 2nd June, 2021; Revised: 10th July, 2021; Accepted: 31th July, 2021; Available Online: 25th September, 2021

ABSTRACT

Liver fibrosis represents the final consequences of repeated occasions of hepatocellular necrosis and hepatic inflammation, regardless of the underlying causes of chronic hepatic disorders. It is manifested as a massive deposition of extracellular matrix (ECMs) within the damaged liver of different chronic hepatic disorders. Moreover, increase in the releases of radical moieties, e.g., superoxide, hydroxyl, and hydrogen peroxide radicals in living cells resulted in homeostatic deregulation and oxidative stress (OS) consequently damaging the biological molecules such as membrane lipids. Changing in cellular composition and level (amount) of antioxidant enzymes, e.g., superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH) due to increased OS might result in chronic liver diseases. Hepatic fibrosis has been documented to be correlated with OS in numerous researches. In the current study 50 white albino rats were allocated as follows: Group I (Healthy Control): 10 rats received 1 mL/kg intraperitoneally (IP) olive oil (vehicle only group) twice a week for 6 weeks. Group II (CCl₄; Induction Group): 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week for 6 weeks. Group III (Silymarin Group): 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week + Silymarin (hepatoprotective agent) (100 mg/kg). Once daily orally for six weeks concurrently with CCl₄. Group IV (Krill Oil Group): 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week + krill oil (400 mg/kg) once daily orally for six weeks concurrently with CCl₄. Group V Combination of (Krill oil+ Silymarin Group): 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week + (krill oil (400 mg/kg) + Silymarin (100 mg/kg)) once daily orally for six weeks concurrently with CCl₄. This study reveals that orally administered krill oil in combination with oral Silymarin significantly ($p < 0.001$) increase the hepatoprotective activity against CCl₄-induced hepatotoxicity in white albino rats through improvements in both liver tissue oxidative stress parameters, and histological features in both MT, and (H&E) stained sections.

Keywords: Carbon Tetrachloride, Hepatoprotection, Krill oil, Rats liver, Silymarin.

International Journal of Drug Delivery Technology (2021); DOI: 10.25258/ijddt.11.3.29

How to cite this article: Ali KH, Al-Jawad FH, Kadhim HM, Al-Dabagh MAH Al-Dabagh. The Possible Hepatoprotective Effects of Combination of an Oral Krill Oil and Silymarin against Carbon Tetrachloride (CCl₄)-induced Liver Fibrosis/Injury in White Albino Rats: Histopathological, and Biochemical Studies. International Journal of Drug Delivery Technology. 2021;11(3):827-833.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Liver fibrosis represents the final consequences of repeated occasions of hepatocellular necrosis and hepatic inflammation, regardless of the underlying causes of the chronic hepatic disorder.¹ It is featured by excessive accumulation of extracellular matrix proteins (ECMs) in the injured liver of different forms of chronic hepatic diseases e.g., ethanol-induced hepatic disease (ALD), non-ethanol -induced fatty liver disease (NAFLD), and steatohepatitis (NASH), cirrhosis, and hepatocellular cancer (HCC).² Of the most crucial cells,

hepatic stellate cells (HSCs) display a fundamental role in the initiation, progression, and regression in hepatic scarring via releasing fibrogenic factors that recruit portal fibrocytes, fibroblasts, and bone marrow-derived myofibroblasts to produce ECM and eventually propagate fibrosis.³ The presence of HSC along with the space of disse allows for the direct contact of the HSC and other cells involving hepatocytes, endothelial cells, and Kupfer cells, therefore enhance the intercellular release of soluble mediators and cytokines. In addition to this proximity presence in the space of Disse,

*Author for Correspondence: pharmasim@yahoo.com

intercellular cross-talking of HSC and adjacent cell types have been shown to be encouraged due to the presence of dendritic cytoplasmic processes.⁴

Moreover, massive synthesis of e radical moieties, such as superoxide, hydroxyl, and hydrogen peroxide by the cells causes homeostatic deregulations in OS, causing damage to biological molecules, e.g., proteins, nucleic acids, and membrane lipids. Changes in cellular constituents and levels of antioxidant enzymes such as superoxide dismutase (SOD), CAT, and reduced GSH due to high oxidative stress might have resulted in chronic hepatic disorder.⁵ Numerous Pathologies of hepatic disorders like chronic hepatitis, fibrosis have been shown to be correlated with OS in different researches.⁶ Carbon tetrachloride (CCl₄) is an extensively researched hepatotoxin in studying the pathogenesis of hepatic damage in various animal models.⁷ Metabolic activation of CCl₄ leads to the production of trichloromethyl and proxy chloromethyl radical moieties, resulting in an imbalance between reactive oxygen species (ROS) and antioxidants and initiating hepatic damage and necrosis. CCl₄ can also activate Kupffer cells by increasing Ca²⁺ levels, initiating the intracellular production of harmful mediators that encourage the death of liver cells and the release of reactive oxygen species.⁸

However, to this date, there was no effective medicine in the clinic for the management of hepatic fibrosis. Accordingly, research on liver antifibrotic agents is a 'hot topic'. The main available treatment strategies for fibrosis focused on treatment of underlying diseases, suppressing the inflammation, targeting ECM synthesis and breakdown, attenuation of hepatic parenchyma cell damage, and apoptosis. Although there were no approved pharmacotherapies for liver fibrosis.⁹ Some drugs and/or combination of two drugs are now in phase III clinical trials for attenuation of primary biliary cirrhosis such as Obetoticholic acid a farnesoid-X- receptor (FXR) agonist, Bezafibrate, an agonist of peroxisome proliferator-activated receptors (PPARs) in phase III clinical trials with ursodeoxycholic acid (UDCA) and other combination therapy.¹⁰ The aim of this research is to investigate the possible potential hepatoprotective effects of krill oil alone and in combination with Silymarin in white albino rats by studying the liver tissues histopathological changes stained with masons trichrome (MT) and hematoxylin and eosin (H&E), and also assessing the oxidative stress markers in both serum and liver tissues samples.

MATERIALS AND METHODS

Chemicals

All chemicals used in the current study were of analytic grades. CCl₄ liquid was supplied by GCC ANALYST (UK), Silymarin by MADUAS[®] (Germany), and Krill Oil from Natrol[®] (USA). The kits for the estimation of serum total antioxidant capacity (TAC) microplate assay kit was purchased from (Cohesion Biosciences, UK), liver tissue homogenates kits: glutathione peroxidases (GPx) ELISA kit from (Elabscience, USA), malondialdehyde (MDA) microplate assay kit (Cohesion Biosciences, UK), myeloperoxidase (MPO) ELISA kit from

(AbbeXa, UK), superoxide dismutase (SOD) microplate assay kit from (Cohesion Biosciences, UK), and Masson's trichrome (MT) collagen staining kit from (COSM BIO CO, USA).

Animals Handling and Experimental Design

Fifty healthy white albino rats of both genders (25 males and 25 females), weighing between (200–250 gm) were utilized in this study. An animal house supplied these animals at Biotechnology Center, Al Nahrain University, Baghdad, Iraq. These animals were placed as five animals in each separated cage. Animals were kept under standard conditions at a temperature between (23±2) °C and 50–60% relative humidity, with 12/12 hours. Light-dark cycles were applied. Animals were subjected to acclimatization for approximately 2 weeks before starting the work. During the acclimatization period and during the whole experimental period, animals were fed a standard laboratory diet and free access to tap water *ad libitum*.^{11,12} Such method was in accordance with approval committee of ethical of laboratory animals handling in the College of Medicine, Al-Nahrain University, Baghdad, Iraq. Animals were categorized for 5 groups (as ten animals per each group) as followed:

- *Group I (Healthy Control Group):* Ten rats received 1 mL/kg IP olive oil (vehicle only group) twice a week for 6 weeks. Group II (CCl₄; Induction Group): 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week for 6 weeks.¹³
- *Group III (Silymarin Group):* A total of 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week + Silymarin (hepatoprotective agent; standard treatment) (100 mg/kg)¹⁴ once daily orally for six weeks concurrently with CCl₄.
- *Group IV (Krill Oil Group):* 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week + krill oil (400 mg/kg) once daily orally for six weeks concurrently with CCl₄.
- *Group V (Combination of (Krill oil+ Silymarin Group)):* 10 rats received 1 mL/kg of 50% CCl₄ solution in olive oil IP twice a week + (krill oil (400 mg/kg) + Silymarin (100 mg/kg)) once daily orally for six weeks concurrently with CCl₄.

Six weeks and 24 hours later, all animals were sacrificed under light anesthesia of Diethyl ether (ether). Liver weights were first documented separately, and tissue samples were collected for homogenization and measurement of proposed oxidative stress tissue parameters (glutathione peroxidase (GPx), malondialdehyde (MDA), myeloperoxidase (MPO), and superoxide dismutase (SOD)), and masson's trichrome (MT) collagen staining, in addition to hematoxylin & eosin staining.¹⁵

Haematoxylin and Eosin (H&E), Masson Trichrome (MT) Staining, and Scoring of Fibrosis

Hepatic tissues were taken and fixed in 4% paraformaldehyde. Paraffin liver sections were dewaxed using xylene, dehydrated with ethanol, rinsed, and stained with hematoxylin for five minutes, washed quickly, and then differentiated by 1% acid alcohol (thirteen seconds) and washing for 10 minutes. Slides were stained with eosin solution for 2–3 minutes,

then washed and mounted. Photographs were acquired using a digital image-capture system.¹⁶

Regarding masson trichrome (MT) staining, the liver section was dewaxed, dehydrated, and rinsed. Firstly- Sections were first stained with Weigert's iron hematoxylin (5 minutes) and rinsed. Secondly- Sections were stained with Biebrich scarlet acid fuchsin solution (5 minutes) and rinsed. Thirdly- sections were differentiated in one percent phosphomolybdic-phosphotungstic acid solution (5 minutes), then transferred to aniline blue solution, and stained for 5 minutes. Fourth- Sections were differentiated in one percent acetic acid (AA) solution for one minute, rinsed, dehydrated, and mounted with an appropriate mounting medium. Images were captured by a digital camera connected to a light microscope. MT (X400 magnification) was examined.¹⁶ Scoring of fibrosis was done according to Ishak scoring system as below:

Grade 0: No fibrosis, Grade I: Fibrous expansion: was established in some of the portal areas, together with/ or without short fibrous septa, Grade II: Fibrous expansion: of most portal areas, with or without short fibrous septa, Grade III: Fibrous expansion: was presumed in nearly most portal areas with an occasional portal to portal (P-P) bridging, Grade IV: Fibrous expansion: was seen in portal areas with marked bridging (P-P) as well as portal-central (P-C), Grade V: distinguished my marked bridging (P-P and/ or P-C) with occasional nodules (incomplete cirrhosis), Grade VI: Cirrhosis, probable /or definite.¹⁷ The frozen tissues were weighed and immediately homogenized at an operating speed of 6000 rpm using homogenizer. For the determination of tissue parameters oxidative stress activity in the liver, the samples were homogenized in 0.1 M phosphate buffer, pH 7.4 for 1 minutes, according to the appropriate kit procedure. Homogenates were next used for biochemical assays.¹⁸

Statistical Analysis

Results from the current study were presented as means \pm standard deviation (M \pm SD) The difference among means had been analyzed by ANOVA using statistical package for social scientists (SPSS) version 20 where *p* values \leq 0.05 were considered to be significant.

RESULTS AND DISCUSSION

Results from the current study presented in Table 1 were revealed that addition of krill oil (Krill) to silymarin (Silym) oral combined therapy (Krill + Silym) as the hepatoprotective agent was produced the most significant result as represented in mean \pm standard deviation (M \pm SD) in Table 1 as compared to each of healthy, induction, Silym, and Krill groups. Regarding tissue homogenate level of glutathione peroxidase (GPx), a combination of (Krill+Silym) was produced most significant elevation in GPx level (M \pm SD = 116.93 \pm 3.57, *p*<0.001) when compared to each of, induction, Silym, and Krill groups. Glutathione peroxidase (GPx) catalyzes the reduction of a variety of hydroperoxides (ROOH and H₂O₂) to water or the corresponding alcohols using GSH to protect mammalian cells against oxidative damage.¹⁹ Therefore, replenishment of GPx

level with oral (Krill+ Silym) administration contributed to significant hepatoprotection and /antioxidant ability of such combination.

Moreover, MDA level in rat liver tissue homogenate in (Krill + Silym) combination group was shown to be the most significant also as being presented with (M \pm SD = 8.51 \pm 0.77, *p*<0.001) as compared to when compared to each of, induction, Silym, and Krill groups Table 1. MDA is a product of lipid peroxidation and the most representative indicator of oxidative stress (OS) in the body, reflecting OS after liver injury. MDA is one of the most commonly used representative indicators of OS injury. It is able to activate Kupffer cells to secrete numerous cytokines, activate hepatic stellate cells (HSC), and mediate HSC differentiation, proliferation, and collagen synthesis.²⁰ In in (Krill + Silym) combination group lowest level was achieved among all other treated groups suggesting excellent hepatoprotection and/ or antioxidant properties against CCl₄-induced liver injury.

Myeloperoxidase (MPO) on the other hand, is a basic metal-containing lysosomal enzyme and part of the organism's host-defense system. MPO uses hydrogen peroxide and halide (Cl⁻, Br⁻, I⁻) or pseudohalide (SCN⁻) ions to catalyze the production of hypochlorous (HOCl), hypobromous (HOBr), hypoiodous (HOI) or hypothiocyanous (HOSCN) acids. The enzyme is capable of catalyzing two types of redox reactions; specifically, the halogenation cycle and the peroxidase cycle.²¹ Combination of (Krill + Silym) were shown to elicit the most significant dropping in liver tissues level of MPO (2.03 \pm 0.15, *p*<0.001) when compared to each of, induction, Silym, and Krill groups Table 1. Furthermore, the combination of (Krill + Silym) was also shown to boost the superoxide dismutase (SOD) level and resulted in the most significant elevation in SOD level (16.68 \pm 1.73, *p*<0.001) when compared to each of, induction, Silym, and Krill groups Table 1. Because SOD offers protection against the harmful effects of ROS²² therefore, a combination of (Krill + Silym) accordingly offered substantial hepatoprotection and/ or antioxidant against CCl₄-induced hepatic injury/fibrosis. Due to its beneficial effects on hepatotoxicity, SOD has also been proposed as an antidote against carbon tetrachloride (CCl₄) intoxication. The CCl₄ metabolic process in the liver gives rise to two active microsomal radicals or peroxides (CCl₃ or CCl₃OO), via the cytochrome P450 pathway, thus causing lipid peroxidation and undermining the integrity of liver-cell membranes.²³

Cheong *et al.*, 2017 were revealed that dietary Krill oil administration was found to protect against oxidative damage, lipid peroxidation and neurodegenerative diseases by significantly improved OS biomarkers e.g., serum SOD and GPx levels of aging mice supplemented.²⁴ such findings support that obtained from the current study.

Krill oil from *Euphausia superba* rich in astaxanthin, a carotenoid antioxidant, belongs to the group of xanthophylls responsible for the color of some plants, animals, and microorganisms, and crustaceans.²⁵ Astaxanthin had been shown to be the most potent antioxidant against lipid peroxidation than D-tocopherols and for single- O₂ neutralizing

than β-carotene.²⁶ Moreover, Krill oil contains high proportions of eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) engaged to phospholipids.²⁷

Regarding the anti-inflammation actions of both EPA, and DHA, it was shown that they lowered serum levels of the acute phase mediators, C-reactive protein (CRP), and also decreased expression of pro-inflammatory mediators, tumor necrosis factor (TNF)-α and interleukin (IL)-6. Furthermore, both EPA and DHA also been documented to lower the blood levels of pro-inflammatory eicosanoids, e.g., thromboxane B₂, and leukotriene B₄.²⁷ The composition of phospholipid classes in krill oil extracted from *Euphausia superba* were separated by HPLC to yield standard mixtures, (phosphatidylethanolamine (PE) and phosphatidylcholine (PC)).²⁸ Krill oil has taken an excellent interest as the PL-bound fatty acids are most highly absorbed and incorporated into cell membranes.²⁹ Therefore,

ensuring excellent delivery and distribution to body tissue and maintaining membrane integrity.

Note: Score 0 corresponds to (1.9%), Score 1 corresponds to (3%), Score 2 corresponds to (3.6%), Score 3 corresponds to (6.5%), Score 4 corresponds to (13.7%), Score 5 corresponds to (24.3%), and Score 6 corresponds to (27.8%) according to (Pradhan S., 2013).

Regarding histopathological features in both MT and (H&E) stained rats liver tissue sections, following 6 weeks (twice weekly) of IP administration of 50% (V/V) CCl₄ in Olive oil, there were significant collagen deposition in CCl₄ treated (induction group) (10.92 ± 8.36, p ≤ 0.001) when compared to each of healthy (M ± SD, 3 ± 0.00), Silym (M ± SD, 4.52 ± 1.82), Krill (M ± SD, 3.24 ± 0.33), and combination of (Krill+Silym) (M ± SD, 3.82 ± 1.52) groups respectively as seen in Table 2. Furthermore, both Krill, and a combination of (Krill+Silym) groups were shown to exhibit the lowest

Table 1: Showed liver tissue homogenate levels of glutathione peroxidase (gpx), malondialdehyde (mda), myeloperoxidase (mpo), and superoxide dismutase (sod) among the studied groups

p value (sig ≤ 0.05)

Group	M ± SD	GPx (Pg/mL)			
		Induction	Silym	Krill	(Krill+ Silym)
Healthy	119.72 ± 3.5	<0.001	<0.001	<0.001	0.15
Induction	70.93 ± 4.68		<0.001	<0.001	<0.001
Silym	83.71 ± 4.98			<0.001	0.001
Krill	95.64 ± 6				<0.001
(Krill+ Silym)	116.93 ± 3.57				
<i>MDA (nmole/g)</i>					
Group	M ± SD	Induction	Silym	Krill	(Krill+ Silym)
Healthy	6.58 ± 0.47	<0.001	<0.001	<0.001	0.15
Induction	14.98 ± 1.18		<0.001	<0.001	<0.001
Silym	13.57 ± 0.61			0.059	<0.001
Krill	12.93 ± 0.47				<0.001
(Krill+ Silym))	8.51 ± 0.77				
<i>MPO (ng/mL)</i>					
Group	M ± SD	Induction	Silym	Krill	(Krill + Silym)
Healthy	1.16 ± 0.15	<0.001	<0.001	<0.001	<0.001
Induction	4.66 ± 0.26		<0.001	<0.001	<0.001
Sylim	3.41 ± 0.19			0.62	<0.001
Krill	3.38 ± 0.15				<0.001
(Krill+ Silym)	2.03 ± 0.15				
<i>SOD (U/g)</i>					
Group	M ± SD	Induction	Silym	Krill	Krill+ Silym
Healthy	17.99 ± 1.88	<0.001	<0.001	<0.001	0.15
Induction	5.18 ± 1.45		0.002	<0.001	<0.001
Silym	8.05 ± 1.81			0.001	<0.001
Krill	11.02 ± 2.93				<0.001
(Krill+ Silym)	16.68 ± 1.73				

GPx: Glutathione peroxidase, MDA: Malondialdehyde, MPO: Myeloperoxidase, SOD: Superoxide dismutase, M: Mean, SD: Standard deviation,, Silym: Silymarin, Krill: Krill oil.




Figure 1: Representative photomicrographs showing in the column (A) Collagen deposition stained with Masson's trichrome stain (mt) within rats liver tissues, and (B) stained with hematoxylin & eosin (H&E); where [(A1,A2,A3,A4,&A5) corresponded to (Induction, Healthy, Silym, Krill, (Krill + Silym) groups stained with MT respectively], while, [(B1,B2,B3,B4,& B5) corresponded to (Induction, Healthy, Silym, Krill, & (Krill + Silym) groups stained with H&E, respectively].

Table 2: Showed liver tissue scores of collagen deposition (fibrosis scores) in masson's trichrome (MT) stained tissues among the studied groups

Group	M ± SD	Fibrosis Scores			
		Induction	Silym	Krill	(Krill+Silym)
Healthy	3 ± 0.00	≤0.001	0.46	0.91	0.69
Induction	10.92±8.36		≤0.001	≤0.001	≤0.001
Silym	4.5±1.82			0.53	0.73
Krill	3.24±0.33				0.78
(Krill+Silym)	3.82±1.52				

M: Mean, SD: Standard deviation, Silym: Silymarin, & Krill: Krill oil.

(M ± SD) regarding collagen deposition (fibrosis), suggesting the highest hepatoprotection activities as illustrated in Figure 1 in section A4, A5, B4, and B5.

CONCLUSION

This study was revealed that orally administered krill oil in combination with oral Silymarin significantly increased the hepatoprotective activity against CCl₄-induced hepatotoxicity in white albino rats through improvements in both liver tissue oxidative stress parameters and histological features in both MT, and (H&E) stained sections.

REFERENCES

- Ballestri S., Mantovani A., Baldelli E., Lugari, S. Maurantonio M., Nascimbeni F., Marrazzo A., Romagnoli D., Targher G., & Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. *Diagnostics* 2021; 11(98):1-19.
- Yang M., and Zhang C. The role of bone morphogenetic proteins in liver fibrosis (minireview). *Gastroenterology & Hepatology* 2021; 12(1):1-4.
- Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. *World J Gastroenterol* 2016; 22(48):10512-10522
- Tanwar S, Rhodes F, Srivastava A, Trembling PM, & Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. *World J Gastroenterol* 2020; 26(2):109-133.
- Lamia, S.S., Emran, T., Rikta, J.K., Chowdhury, N.I.; Sarker, M., Jain, P.; Islam, T.; Gias, Z.T., Shill, M.C., & Reza H.M. Coenzyme Q10 and Silymarin Reduce CCl₄-Induced Oxidative Stress and Liver and Kidney Injury in Ovariectomized Rats—Implications for Protective Therapy in Chronic Liver and Kidney Diseases. *Pathophysiology* 2021; 28: 50–63.
- Saha P., Talukdar A.D., Nath R., Sarker S.D., Nahar L., Sahu J., & Choudhury M.D. Role of Natural Phenolics in Hepatoprotection: A Mechanistic Review and Analysis of Regulatory Network of Associated Genes. *Front. Pharmacol.* 2019, 10, 509.
- Adebayo AH, Yakubu OF, & Balogun, TM Protective properties of Citrullus lanatus on carbon tetrachloride induced liver damage in rats. *Eur. J. Med. Plants* 2014; 4: 979-989.
- Boll M., Lutz W., Becker E., & Stampf A. Mechanism of carbon tetrachloride-induced hepatotoxicity. Hepatocellular damage by

- reactive carbon tetrachloride metabolites. *Z. Naturforsch. C* 2001, 56, 649-659.
- Chang Y., & Li, H. Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?. *Journal of clinical and translational hepatology*, 2020; 8(2), 222-229.
- Guo YC, & Lu LG. Antihepatic Fibrosis Drugs in Clinical Trials. Review. *J Clin Transl Hepatol* 2020; 8(4):1-9.
- Kołota A, Głabska D, Oczkowski M, & Gromadzka-Ostrowska J. Oxidative Stress Parameters in the Liver of Growing Male Rats Receiving Various Alcoholic Beverages. *Nutrients*. 2020; 12(1):1-14.
- Patil S.D, Patil L., & Kadam VJ Protective Effect of Ethanolic Extract of Fruit of Luffa aegyptiaca Mill. on Carbon Tetrachloride Induced Hepatotoxicity in Rats. *Research J. Pharm. and Tech.* 2011; 4(6): 938-941.
- Shukla A., & Bigoniya P. Hepatoprotective Effect of Lepidium Sativum Linn (Cruciferae) Total Alkaloid Fraction against CCl₄ Induced Hepatotoxicity on Rats. *Research J. Pharmacognosy and Phytochemistry* 2013; 5(2): 94-99.
- Sahu S. K., Das D., & Tripathy S. K. Hepatoprotective activity of aerial part of Glinus oppositifolius L. against Paracetamol-induced Hepatic Injury in Rats. *Asian J. Pharm. Tech.* 2012; 2(4):154-156.
- Patel J., Reddy V., Kumar GS. Evaluation of hepatoprotective activity of ethanolic extract of Diospyros melanoxylon (Roxb) leaves against CCl₄ induced hepatotoxicity in albino rats. *Research J. Pharm. and Tech.* 2015; 8(5): 571-574.
- Khalil MR, El-Demerdash RS, Elminshawy HH, Mehanna ET, Mesbah NM, & Abo-Elmatty DM. Therapeutic effect of bone marrow mesenchymal stem cells in a rat model of carbon tetrachloride induced liver fibrosis. *Biomed J.* 2020; S2319-4170(20)30048-2.
- Arjmand A., Tsiouras M.G., Tzallas A.T., Forlano R., Manousou P., & Giannakeas N. Quantification of Liver Fibrosis—A Comparative Study. *Applied Science* 2020; 10(447): 1-34.
- Górny M, Bilska-Wilkosz A, Iciek M, Hereta M, Kamińska K, Kamińska A, Chwatko G, Rogóż Z, Lorenc-Koci E. Alterations in the Antioxidant Enzyme Activities in the Neurodevelopmental Rat Model of Schizophrenia Induced by Glutathione Deficiency during Early Postnatal Life. *Antioxidants (Basel)*. 2020 19; 9(6):538.
- Lee KH, Cha M, & Lee BH. Neuroprotective Effect of Antioxidants in the Brain. *Int J Mol Sci.* 2020; 21(19): 1-29.
- Cheng DL, Zhu N, Li CL, Lv WF, Fang WW, Liu Y, & Li CT. Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model. *Exp Ther Med.* 2018; 16: 5227-5235.
- Kargapolova Y, Geißen S, Zheng R, Baldus S, Winkels H, & Adam M. The Enzymatic and Non-Enzymatic Function of Myeloperoxidase (MPO) in Inflammatory Communication. *Antioxidants* 2021; 10(4):1-18.
- Tsai MY, Yang WC, Lin CF, Wang CM, Liu HY, Lin CS, Lin JW, Lin WL, Lin TC, Fan PS, Hung KH, Lu YW, & Chang GR. The Ameliorative Effects of Fucooidan in Thioacetamide-Induced Liver Injury in Mice. *Molecules* 2021; 26(7):1-18.
- Rosa AC, Corsi D, Cavi N, Bruni N, & Dosio F. Superoxide Dismutase Administration: A Review of Proposed Human Uses. *Molecules* 2021 25; 26(7):1-40.
- Cheong LZ, Sun T, Li Y, Zhou J, Lu C, Li Y, Huang Z, & Su X. Dietary krill oil enhances neurocognitive functions and

- modulates proteomic changes in brain tissues of d-galactose induced aging mice. *Food Funct.* 2017;8(5):2038-2045.
25. Martínez-Álvarez Ó, Calvo MM, Gómez-Estaca J. Recent Advances in Astaxanthin Micro/Nanoencapsulation to Improve Its Stability and Functionality as a Food Ingredient. *Mar Drugs.* 2020;18(8):1-25.
26. El-Bialy HAA, & Abd El-Khalek. HHA comparative study on astaxanthin recovery from shrimp wastes using lactic fermentation and green solvents:an applied model on minced Tilapia, *Journal of Radiation Research and Applied Sciences* 2020; 13 (1): 594-605.
27. Innes JK, & Calder PC. Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020. *Int J Mol Sci.* 2020;21(4):1-21.
28. Zhou L, Yang F, Zhang M, &Liu J. A Green Enzymatic Extraction Optimization and Oxidative Stability of Krill Oil from *Euphausia Superba*. *Mar Drugs.* 2020;18(2):1-16.
29. Ramprasath VR, Eyal I, Zchut S, Shafat I, & Jones PJ. Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. *Lipids Health Dis.* 2015; 14:1-9.